Macro Biologics, Inc.
Macro Biologics, Inc. is dedicated to designing, patenting, and producing macro biologics, which are large molecule biologics with both physical properties and functional activities. These biologics are composed of natural building blocks, such as amino acids or carbohydrates, and are designed to degrade back into their natural components, making them environmentally friendly. The company aims to address significant global challenges, such as antibiotic resistance and pollution, by providing biologics that are safe for both people and the environment. Macro Biologics is committed to the highest standards of science, medicine, and business, with a focus on healthcare applications.
Industries
Nr. of Employees
small (1-50)
Macro Biologics, Inc.
3142 Tiger Run Court - Suite 101, Carlsbad, California 92010
Awards
Amicidin-alpha Prolonged Field Care Product
Funding (ceiling)
$3,993,000
Award Year
2021
Products
Investigational topical surgical gel (large-molecule antimicrobial biologic)
An investigational intraoperative gel designed for direct application to exposed tissues to provide a physical barrier and broad microbicidal activity to prevent surgical-site infections in clean and clean-contaminated procedures.
Investigational prolonged-field-care powder-to-gel wound treatment
A dry powder formulation intended for use in prolonged field-care settings that rapidly gels on exposure to moisture to create an active barrier with antimicrobial activity for up to 72 hours; designed to be lightweight and compact for field deployment.
Investigational antimicrobial solution for contaminated/infected tissues
An investigational aqueous formulation combining surfactant-based cleansing/debridement activity with broad microbicidal effects, intended as an adjunct to surgical treatment of contaminated and infected wounds.
Investigational extended formulation for emergency and trauma settings
A formulation designed to increase tissue coverage (including cavities) for emergency and traumatic wounds; adaptable as a liquid or foam for use in emergency cesarean delivery and open fractures, including low- and middle-income settings.
Investigational topical surgical gel (large-molecule antimicrobial biologic)
An investigational intraoperative gel designed for direct application to exposed tissues to provide a physical barrier and broad microbicidal activity to prevent surgical-site infections in clean and clean-contaminated procedures.
Investigational prolonged-field-care powder-to-gel wound treatment
A dry powder formulation intended for use in prolonged field-care settings that rapidly gels on exposure to moisture to create an active barrier with antimicrobial activity for up to 72 hours; designed to be lightweight and compact for field deployment.
Investigational antimicrobial solution for contaminated/infected tissues
An investigational aqueous formulation combining surfactant-based cleansing/debridement activity with broad microbicidal effects, intended as an adjunct to surgical treatment of contaminated and infected wounds.
Investigational extended formulation for emergency and trauma settings
A formulation designed to increase tissue coverage (including cavities) for emergency and traumatic wounds; adaptable as a liquid or foam for use in emergency cesarean delivery and open fractures, including low- and middle-income settings.
Expertise Areas
- Topical antimicrobial biologic therapeutics
- Surgery and trauma infection prevention
- Biomaterials engineering (amino-acid-based polymers)
- Formulation development for gels, powders, foams, and solutions
Key Technologies
- Amino-acid-based block copolymer synthesis
- Engineered macromolecular biologics (biologics-as-materials)
- Moisture-activated powder-to-gel formulations
- Topical gel, foam and aqueous solution formulations
Key People
CEO, CSO, Director & Co-Founder
Head of SAB & Co-Founder
Vice President of Operations
Director of Preclinical Development
Associate Director of Materials Science
Associate Director of Corporate Dev.
CEO, CSO, Director & Co-Founder
Head of SAB & Co-Founder
Vice President of Operations
Director of Preclinical Development
Associate Director of Materials Science
Associate Director of Corporate Dev.
Investors
CARB-X
$4,600,000 funded.
Announced on 2020-06-23.
Debt Financing - Amicrobe
$2,500,000 funded.
Announced on 2020-02-12.
CARB-X
$2,480,000 funded.
Announced on 2017-10-24.
Series C - Amicrobe
$5,000,000 funded.
Announced on 2017-09-06.
CARB-X
$4,600,000 funded.
Announced on 2020-06-23.
Debt Financing - Amicrobe
$2,500,000 funded.
Announced on 2020-02-12.
CARB-X
$2,480,000 funded.
Announced on 2017-10-24.
Series C - Amicrobe
$5,000,000 funded.
Announced on 2017-09-06.
News & Updates
Macro Biologics partners with Beiersdorf to develop antimicrobial peptides.
Macro Biologics to present at the World AMR Congress 2024.
Amicrobe changes its name to Macro Biologics.
Macro Biologics partners with Beiersdorf to develop antimicrobial peptides.
Macro Biologics to present at the World AMR Congress 2024.
Amicrobe changes its name to Macro Biologics.